CSIMarket
 


Scynexis Inc   (SCYX)
Other Ticker:  
 

Scynexis Inc 's Quick Ratio

SCYX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Scynexis Inc 's Cash & cash equivalent grew by 56.04 % in the II Quarter 2023 sequentially, while Current Liabilities decreased, this led to improvement in Scynexis Inc 's Quick Ratio to 5.29, Quick Ratio remained below Scynexis Inc average.

Within Major Pharmaceutical Preparations industry 187 other companies have achieved higher Quick Ratio than Scynexis Inc in second quarter 2023. While Quick Ratio total ranking has improved so far during the II Quarter 2023 to 549, from total ranking in the first quarter 2023 at 1599.

Explain Quick Ratio?
How much Cash & cash equivalents SCYX´s has?
What are SCYX´s Current Liabilities?


SCYX Quick Ratio (Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
Y / Y Current Liabilities Change 2.18 % 250.34 % 27.98 % 5.86 % -20.45 %
Y / Y Cash & cash equivalent Change -27.93 % -42.42 % -29.65 % -4.01 % 5.55 %
Quick Ratio MRQ 5.29 1.21 4.24 6.87 7.51
SCYX's Total Ranking # 549 # 1599 # 816 # 618 # 479
Seq. Current Liabilities Change -64.37 % 161.58 % 23.87 % -11.5 % 22.16 %
Seq. Cash & cash equivalent Change 56.04 % -25.42 % -23.51 % -19.04 % 24.66 %



Quick Ratio second quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 188
Healthcare Sector # 319
Overall Market # 549


Quick Ratio Statistics
High Average Low
20.74 7.29 0.03
(Sep 30 2015)   (Mar 31 2014)




Financial Statements
Scynexis Inc 's Current Liabilities $ 16 Millions Visit SCYX's Balance sheet
Scynexis Inc 's Cash & cash equivalent $ 86 Millions Visit SCYX's Balance sheet
Source of SCYX's Sales Visit SCYX's Sales by Geography


Cumulative Scynexis Inc 's Quick Ratio

SCYX's Quick Ratio for the trailling 12 Months

SCYX Quick Ratio

(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
Y / Y Current Liabilities TTM Growth 2.18 % 250.34 % 27.98 % 5.86 % -20.45 %
Y / Y Cash & cash equivalent TTM Growth -27.93 % -42.42 % -29.65 % -4.01 % 5.55 %
Quick Ratio TTM 3.34 3.71 6.38 7.36 7.54
Total Ranking TTM # 483 # 773 # 3486 # 335 # 546
Seq. Current Liabilities TTM Growth -64.37 % 161.58 % 23.87 % -11.5 % 22.16 %
Seq. Cash & cash equivalent TTM Growth 56.04 % -25.42 % -23.51 % -19.04 % 24.66 %


On the trailing twelve months basis Due to drop in Current Liabilities in the II Quarter 2023 to $16.16 millions, cumulative Quick Ratio decreased to 3.34 below the Scynexis Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 205 other companies have achieved higher Quick Ratio than Scynexis Inc . While Quick Ratio overall ranking has improved so far to 483, from total ranking during the twelve months ending first quarter 2023 at 773.

Explain Quick Ratio?
How much Cash & cash equivalents SCYX´s has?
What are SCYX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 206
Healthcare Sector # 348
Within the Market # 483


trailing twelve months Quick Ratio Statistics
High Average Low
13.1 6.41 3.31
(Jun 30 2017)   (Jun 30 2023)




Companies with similar Quick Ratio in the quarter ending Jun 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2023 MRQ Cash & cash equivalentJun 30 2023 MRQ Current Liabilities
Larimar Therapeutics Inc   14.32 $ 104.200  Millions$ 7.275  Millions
Lipocine Inc   14.11 $ 25.790  Millions$ 1.827  Millions
Verve Therapeutics Inc   14.00 $ 462.476  Millions$ 33.031  Millions
Anixa Biosciences Inc   13.75 $ 25.534  Millions$ 1.857  Millions
Artelo Biosciences Inc   13.72 $ 8.272  Millions$ 0.603  Millions
Erasca Inc   13.62 $ 317.245  Millions$ 23.292  Millions
Syndax Pharmaceuticals Inc   13.46 $ 406.024  Millions$ 30.168  Millions
Annovis Bio inc   13.41 $ 15.725  Millions$ 1.173  Millions
Rapt Therapeutics Inc   13.30 $ 204.998  Millions$ 15.414  Millions
Caladrius Biosciences Inc   13.23 $ 57.626  Millions$ 4.356  Millions
Protagonist Therapeutics inc   13.08 $ 313.401  Millions$ 23.952  Millions
Rani Therapeutics Holdings Inc   13.01 $ 74.606  Millions$ 5.735  Millions
Pasithea Therapeutics Corp   13.00 $ 26.770  Millions$ 2.059  Millions
Atai Life Sciences N v   12.92 $ 227.492  Millions$ 17.604  Millions
Milestone Pharmaceuticals inc   12.86 $ 87.591  Millions$ 6.809  Millions
Cogent Biosciences Inc   12.79 $ 329.399  Millions$ 25.757  Millions
Immutep Limited  12.63 $ 123.418  Millions$ 9.772  Millions
Cryoport inc   12.57 $ 505.884  Millions$ 40.254  Millions
Dermata Therapeutics Inc   12.36 $ 8.439  Millions$ 0.683  Millions
Lianbio  12.35 $ 267.268  Millions$ 21.642  Millions
Xenetic Biosciences Inc   12.31 $ 10.726  Millions$ 0.871  Millions
Alx Oncology Holdings Inc  12.11 $ 212.836  Millions$ 17.572  Millions
Generation Bio Co   11.86 $ 314.143  Millions$ 26.479  Millions
Infinity Pharmaceuticals Inc   11.81 $ 17.746  Millions$ 1.502  Millions
Briacell Therapeutics Corp   11.80 $ 21.251  Millions$ 1.802  Millions
Kinnate Biopharma Inc   11.71 $ 184.703  Millions$ 15.773  Millions
Gh Research Plc  11.70 $ 78.420  Millions$ 6.701  Millions
Compass Pathways Plc  11.62 $ 148.485  Millions$ 12.775  Millions
Inozyme Pharma Inc   11.61 $ 140.247  Millions$ 12.081  Millions
Phathom Pharmaceuticals Inc   11.55 $ 248.847  Millions$ 21.545  Millions

Date modified: 2023-08-16T17:06:28+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com